Seers to lead communal harmony march in Uttara Kannada

Kolkata, Feb 2: A protester at Park Circus, known as Shaheen Bagh of Kolkata, died last night after she fell ill during her agitation against CAA, NRC and NPR.

The woman has been identified as Sameeda Khatun (57) who was a resident of Entally area of the city. According to protesters, Khatun who was asthmatic patient died after suffering a cardiac arrest. She is survived by husband and eight children.

Around 250 women from Kolkata have been holding a peaceful sit-in at Park Circus Maidan since January 7 to protest against CAA, NRC and NPR and demanding the withdrawal of the new citizenship law.

Research Scholar at Rabindra Bharati University, Nousheen Baba Khan who has been spearheading the Park Circus protest since the beginning, told the newspaper, “Sameeda Khatun was a regular face at the protest and she was not well as she had asthma.

Last evening she came to me complaining that she is having trouble in breathing. We immediately took her to Chittaranjan Hospital where doctors said she had suffered a cardiac arrest. We later took her to Islamia Hospital where doctors declared her brought dead,” said Khan.

Mangaluru, Jan 23: With the results of Joint Entrance Examination (JEE-Main) out, it is celebration time at CFAL (Centre for Advanced Learning), Mangalore’s top training institute as 12 of its students have secured above 99 percentile, out of 120 students who appeared at the prestigious national examination held in January this year. The students are: Kaustubh Rao (99.79), Ujwal Kumar (99.77), Dheeraj Kamath (99.74), Pramod Rao (99.68), Santhosh M (99.59), Mohan Nayak (99.49), Rihan D’silva (99.43), Rishan D’silva (99.41), Pranav Rao (99.41), Aamod BK (99.29), Anmol J Shetty (99.22) and Madhura Sabhahit (99.083).

Apart from the above students, 8 students have scored above 98 percentile, the details of the students are: D.K. Goutham (98.67), Tejah S.S. (98.49), Akash Shetty (98.4), Tejas Bhat K (98.34), Ninaad PS (98.31), Shreepoorna Rao (98.3), K. Annapoorna Prabhu (98.3) and Rakshith Sajjan (98.2). The results of many more students are awaited.

A total of 8,69,010 students had appeared in the said exam from across India. The students who have attempted the JEE Main exam in January can attempt the exams again in April to better their percentile. Students who clear JEE Main qualify for JEE Advanced and are eligible for seats at the NIT’s and other top institutions of the country.

JEE – The most challenging undergraduate admission test

Joint Entrance Examination (JEE) conducted this year by National Testing Agency (NTA) is a national level examination for students to qualify and pursue engineering degree at under graduate level. Paper 1 is held for BE/B.Tech admissions and Paper 2 for B. Arch/B. Planning. JEE Main is a critical criterion for admission in India’s most prestigious and elite universities like IITs and NIT’s.

Those students who clear JEE Main can take the JEE advanced – which is a pre-requisite requirement for admission in the Indian Institute of Technology and Indian School of Mines (Dhanbad)

CFAL – The first name in training

The training at CFAL consists of defined hours of classes, tests and mock exams, unique course material, experienced professors and hence is the first choice for students appearing for STEM examinations including JEE, NTSE, KYPY, OLYMPIADS etc.  The centre was established with the intention of giving students of Mangalore information, guidance and tools required to qualify the competitive exams. However, the main aim of CFAL is to inculcate passion for Math and Science learning among students and to encourage research and innovation in the subjects.

The United States of America has bought almost the entire world's supply of remdesivir, one of just two drugs proven to treat COVID-19. 

“President Trump has struck an amazing deal to ensure Americans have access to the first authorised therapeutic for Covid-19,” said the US health and human services secretary, Alex Azar. 

“To the extent possible, we want to ensure that any American patient who needs remdesivir can get it. The Trump administration is doing everything in our power to learn more about life-saving therapeutics for Covid-19 and secure access to these options for the American people.”

The announcement implies that no other country in the world will be able to buy remdesivir for next three months at least.

The anti-viral drug patented by the US-based Gilead biotech firm is the only one approved by the European Medicines Agency (EMA) to treat patients with the novel coronavirus.

The Trump administration has already shown that it is prepared to outbid and outmanoeuvre all other countries to secure the medical supplies it needs for the US.

“They’ve got access to most of the drug supply [of remdesivir], so there’s nothing for Europe,” said Dr Andrew Hill, senior visiting research fellow at Liverpool University.

Remdesivir, the first drug approved by licensing authorities in the US to treat Covid-19, is made by Gilead and has been shown to help people recover faster from the disease. 

The first 140,000 doses, supplied to drug trials around the world, have been used up. The Trump administration has now bought more than 500,000 doses, which is all of Gilead’s production for July and 90% of August and September.